Risk factors of septic shock in patients with hematologic malignancies and pseudomonas infections

Hematology

Volumn 16, Issue 3, 2011, Pages 160-165

  Jeddi, Ramzi ^a   Ghédira, Héla ^a   Amor, Ramzi Ben ^a   Turki, Amel ^b   Kacem, Karima ^a   Abdennebi, Yosr Ben ^a   Lakhal, Raihane Ben ^a   Aissaoui, Lamia ^a   Abid, Héla Ben ^a   Hadjali, Zaher Bel ^a   Meddeb, Balkis ^a  

^a Department of Hematology ^*  (Tunisia)

^b Hopital Aziza Othmana   (Tunisia)

Author keywords

Neutropenia; Pseudomonas; Septic shock

Indexed keywords

AMIKACIN; C REACTIVE PROTEIN; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; HEMOGLOBIN; LACTIC ACID; PHOSPHATE; PIPERACILLIN; PROCALCITONIN; TAZOBACTAM;

ACUTE LEUKEMIA; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOPHOSPHATEMIA; HYPOPROTEINEMIA; INFECTION RISK; LACTATE BLOOD LEVEL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS FLUORESCENS; PSEUDOMONAS INFECTION; PSEUDOMONAS PUTIDA; RECURRENT INFECTION; RESPIRATORY TRACT DISEASE; RISK FACTOR; SEPTIC SHOCK; SKIN DEFECT;

ACUTE DISEASE; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HOST-PATHOGEN INTERACTIONS; HUMANS; LEUKEMIA; LYMPHOMA; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RISK FACTORS; SHOCK, SEPTIC; SURVIVAL RATE; YOUNG ADULT;

EID: 79958699192     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453311X12953015767293     Document Type: Article

References (41)

1. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on pseudomonas aeruginosa. Chest 2004;124:62S-69S.
2. Comolli JC, Hauser AR, Waite L, Whitchurch CB, Mattick JS, Engel JN. Pseudomonas aeruginosa gene products PilT and PilU are required for cytotoxicity in vitro and virulence in a mouse model of acute pneumonia. Infect Immun 1999;67:3625-30.
3. Kang PJ, Hauser AR, Apodaca G, Fleiszig SM, Wiener-Kronish J, Mostov K, et al. Identification of Pseudomonas genes required for epithelial cell injury. Mol Microbiol 1997;24:1249-62.
4. Mattick JS. Type IV pili and twitching motility. Annu Rev Micrbiol 2002;56:289-314.
5. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases, 5th ed, Vol. 2. Philadelphia (PA): Chircill Livingstone; 2000. p. 2310-9.
6. Bisbe J, Gatell JM, Puig J, Mallolas J, Martinez JA, Jimenez de Anta MT, et al. Pseudomonas aeruginosa bacteremia: univariate and multivariate analyses of factors influencing the prognosis in 133 episodes. Rev Infect Dis 1998;10:629-35.
7. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patient with cancer. Retrospective analysis of 245 episodes. Arch Intern Med 2000;160:501-9.
8. Gallagher PG, Watenakunakorn C. Pseudomonas bacteremia in a community teaching hospital, 1980-1984. Rev Infect Dis 1989;11:846-52.
9. Vidal F, Mensa J, Almela M, Mart́inez JA, Marco F, Casals C, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996;156:2121-6.
10. Kuikha A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish University Hospital. Eur J Clin Microbiol Infect Dis 1998;17:701-8.
11. Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, et al. From the infectious diseases society of America. Guidelines for the use of the antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
12. Scimpff SC, Greene WH, Young VM, Wiernick PH. Significance of Pseudomonas aeruginosa in the patient with leukemia and lymphoma. J Infect Dis 1974;130(Suppl):S24-31.
13. Tapper ML, Armstrong D. Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. J Infect Dis 1974;130(Suppl):S14-S23.
14. Osmon S, Ward S, Frakr VJ, Kollef MH. Hospital mortality for patients with bacteremia due to staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004;125:607-16.
15. Kollef MH. Inadequate antimicrobial treatment: an important determinant of hospitalized patients. Clin Infect Dis 2000;31:S131-8.
16. Kollef MH, Sherman G, Ward S, Fraser FJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
17. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcome in the ICU setting. Chest 2000;118:146-55.
18. Carnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar AE, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-51.
19. Ohmagari N, Hanna H, Graviss L, Hackett B, Perego C, Gonzalez V. Risk factors for infection with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005;104:205-12.
20. Carmeli Y, Troiller N, Karchmer AW, Somoh MH. Health and economic outcomes of antibiotic resistance in pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-32.
21. Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA. Colistin is effective in treatment of infections caused by Multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007;51:1905-11.
22. Hammoud SP, Baden LR. Antibiotic prophylaxis during chemotherapy-induced neutropenia for patients with acute leukemia. Curr Hematol Malig Rep 2007;2:97-103.
23. Sevransky J. Clinical assessment of hemodynamically unstable patients. Curr Opin Crit Care 2009;15:234-8.
24. Arkader R, Troster EJ, Lopes MR, Júnior RR, Carcillo JA, Leone C, et al. Procalcitonin does discriminate between sepsis and systemic inflammatory response syndrome. Arch Dis Child 2006;91:117-20.
25. James JH, Luchette FA, McCarter FD, Fischer JE. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 1999;354:505-8.
26. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004;32:1637-42.
27. Rivers EP, McIntyre L, Morro DC, Rivers KK. Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity. CMAJ 2005;173:1054-65.
28. Spronk PE, Zandestra DF, Ince C. Bench-to-bedside review: sepsis is a disease of the microcirculation. Crit Care 2004;8:462-8.
29. Aduen J, Bernstein WK, Khastgir T, Miller J, Kerzner R, Bhatiani A, et al. The use and clinical importance of a substrate-specific electrode for rapid determination of blood lactate concentrations. JAMA 1994;272:1678-85.
30. Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 2003;78:869-81.
31. Jeddi R, Achour M, Ben Amor R, Aissaoui L, Bouterâ W, Kacem K, et al. Factors associated with severe sepsis: prospective study of 94 neutrpenic febrile episodes. Hematology 2010;15:28-32.
32. Brunelli SM, Goldfarb S. Hypophosphatemia: clinical consequences and management. J Am Soc Nephrol 2007;18:1999-2003.
33. Wilkes P. Hypoproteinemia, strong ion difference, and acid-base status in critically ill patients. J Appl Physiol 1998;84:1740-8.
34. Margrson MP, Soni NC. Effects of albumin supplementation on microvascular permeability in septic patients. J Appl Physiol 2001;92:2139-45.
35. Osih RB, McGregor JC, Rich SE, Moore AC, Furuno JP, Perencevich EN, et al. Impact of empiric antibiotic therapy on outcome in patients with pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007;51:839-44.
36. Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998;2:211-5.
37. Aliago L, Mediavilla JD, Cobo F. A clinical index predicting mortality with Pseudomonas aeruginosa bacteraemia. J Med Microbiol 2002;51:615-9.
38. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985;145:1621-9.
39. Bryan CS, Reynolds KL, Brenner ER. Analysis of 1,186 episodes of Gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983;5:629-38.
40. Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections caused by antibiotic resistant Gram-negative bacilli: risk factors for mortality and influence delayed receipt of antimicrobial therapy on clinical outcome. Clin Infect Dis 2003;37:745-51.
41. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y, et al. Epidemiology and clinical outcome of patients with multiresistant pseudomonas aerugi-nosa. Clin Infect Dis 1999;28:1128-33.